APO Research
Talk to an analyst

APO RESEARCH · REPORT

Somatostatin Analogue Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Somatostatin Analogue Drug Market Outlook and Growth Opportunities 2026

30 December 2025198 pages

Choose your research edition.

Industry ResearchSomatostatin Analogue Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Somatostatin Analogue Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Somatostatin Analogue Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Somatostatin Analogue Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Somatostatin Analogue Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Somatostatin Analogue Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Somatostatin Analogue Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Somatostatin Analogue Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Somatostatin Analogue Drug market include Teva Pharmaceutical Industries Ltd., Novartis AG, Eli Lilly & Co., Pfizer Inc., Tarveda Therapeutics Inc., Ipsen Group, F. Hoffmann-La Roche Ltd., Chiasma and Camurus AB, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Somatostatin Analogue Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Somatostatin Analogue Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Somatostatin Analogue Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Somatostatin Analogue Drug market.

Somatostatin Analogue Drug Segment by Company

Teva Pharmaceutical Industries Ltd.

Novartis AG

Eli Lilly & Co.

Pfizer Inc.

Tarveda Therapeutics Inc.

Ipsen Group

F. Hoffmann-La Roche Ltd.

Chiasma

Camurus AB

Boehringer Ingelheim International GmbH

Somatostatin Analogue Drug Segment by Type

Octreotide

Lanreotide

Pasireotide

Somatostatin Analogue Drug Segment by Application

Acromegaly

Neuroendocrine Tumor (NET)

Others

Somatostatin Analogue Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Somatostatin Analogue Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Somatostatin Analogue Drug key companies, revenue, market share, and recent developments.

3. To split the Somatostatin Analogue Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Somatostatin Analogue Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Somatostatin Analogue Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Somatostatin Analogue Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Analogue Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Analogue Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Analogue Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Somatostatin Analogue Drug industry.

Chapter 3: Detailed analysis of Somatostatin Analogue Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Somatostatin Analogue Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Somatostatin Analogue Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Somatostatin Analogue Drug Industry Trends Table 2. Somatostatin Analogue Drug Industry Drivers Table 3. Somatostatin Analogue Drug Industry Opportunities and Challenges Table 4. Somatostatin Analogue Drug Industry Restraints Table 5. Global Somatostatin Analogue Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Somatostatin Analogue Drug Revenue Share by Company (2021-2026) Table 7. Global Somatostatin Analogue Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Somatostatin Analogue Drug Key Company Manufacturing Base & Headquarters Table 9. Global Somatostatin Analogue Drug Company, Product Type & Application Table 10. Global Somatostatin Analogue Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Somatostatin Analogue Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Octreotide Table 15. Significant Companies of Lanreotide Table 16. Significant Companies of Pasireotide Table 17. Global Somatostatin Analogue Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Somatostatin Analogue Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Somatostatin Analogue Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Somatostatin Analogue Drug Sales Value Share by Type (2021-2026) Table 21. Global Somatostatin Analogue Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Acromegaly Table 23. Significant Companies of Neuroendocrine Tumor (NET) Table 24. Significant Companies of Others Table 25. Global Somatostatin Analogue Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Somatostatin Analogue Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Somatostatin Analogue Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Somatostatin Analogue Drug Sales Value Share by Application (2021-2026) Table 29. Global Somatostatin Analogue Drug Sales Value Share by Application (2027-2032) Table 30. Global Somatostatin Analogue Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Somatostatin Analogue Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Somatostatin Analogue Drug Sales Value Share by Region (2021-2026) Table 33. Global Somatostatin Analogue Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Somatostatin Analogue Drug Sales Value Share by Region (2027-2032) Table 35. Global Somatostatin Analogue Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Somatostatin Analogue Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Somatostatin Analogue Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Somatostatin Analogue Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Somatostatin Analogue Drug Sales Value Market Share by Country (2027-2032) Table 40. Teva Pharmaceutical Industries Ltd. Company Information Table 41. Teva Pharmaceutical Industries Ltd. Business Overview Table 42. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Portfolio Table 44. Teva Pharmaceutical Industries Ltd. Recent Development Table 45. Novartis AG Company Information Table 46. Novartis AG Business Overview Table 47. Novartis AG Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis AG Somatostatin Analogue Drug Product Portfolio Table 49. Novartis AG Recent Development Table 50. Eli Lilly & Co. Company Information Table 51. Eli Lilly & Co. Business Overview Table 52. Eli Lilly & Co. Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Eli Lilly & Co. Somatostatin Analogue Drug Product Portfolio Table 54. Eli Lilly & Co. Recent Development Table 55. Pfizer Inc. Company Information Table 56. Pfizer Inc. Business Overview Table 57. Pfizer Inc. Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer Inc. Somatostatin Analogue Drug Product Portfolio Table 59. Pfizer Inc. Recent Development Table 60. Tarveda Therapeutics Inc. Company Information Table 61. Tarveda Therapeutics Inc. Business Overview Table 62. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Portfolio Table 64. Tarveda Therapeutics Inc. Recent Development Table 65. Ipsen Group Company Information Table 66. Ipsen Group Business Overview Table 67. Ipsen Group Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Ipsen Group Somatostatin Analogue Drug Product Portfolio Table 69. Ipsen Group Recent Development Table 70. F. Hoffmann-La Roche Ltd. Company Information Table 71. F. Hoffmann-La Roche Ltd. Business Overview Table 72. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Portfolio Table 74. F. Hoffmann-La Roche Ltd. Recent Development Table 75. Chiasma Company Information Table 76. Chiasma Business Overview Table 77. Chiasma Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Chiasma Somatostatin Analogue Drug Product Portfolio Table 79. Chiasma Recent Development Table 80. Camurus AB Company Information Table 81. Camurus AB Business Overview Table 82. Camurus AB Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Camurus AB Somatostatin Analogue Drug Product Portfolio Table 84. Camurus AB Recent Development Table 85. Boehringer Ingelheim International GmbH Company Information Table 86. Boehringer Ingelheim International GmbH Business Overview Table 87. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Portfolio Table 89. Boehringer Ingelheim International GmbH Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Somatostatin Analogue Drug Product Image Figure 2. Global Somatostatin Analogue Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Somatostatin Analogue Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Somatostatin Analogue Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Octreotide Image Figure 8. Lanreotide Image Figure 9. Pasireotide Image Figure 10. Global Somatostatin Analogue Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Somatostatin Analogue Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Somatostatin Analogue Drug Sales Value Share by Type (2021-2032) Figure 13. Acromegaly Image Figure 14. Neuroendocrine Tumor (NET) Image Figure 15. Others Image Figure 16. Global Somatostatin Analogue Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Somatostatin Analogue Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Somatostatin Analogue Drug Sales Value Share by Application (2021-2032) Figure 19. Global Somatostatin Analogue Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Somatostatin Analogue Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Somatostatin Analogue Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Somatostatin Analogue Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Somatostatin Analogue Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Somatostatin Analogue Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Somatostatin Analogue Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Somatostatin Analogue Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Somatostatin Analogue Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Somatostatin Analogue Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Somatostatin Analogue Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Somatostatin Analogue Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Octreotide
  • Lanreotide
  • Pasireotide
Applications
  • Acromegaly
  • Neuroendocrine Tumor (NET)
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Tarveda Therapeutics Inc.
  • Ipsen Group
  • F. Hoffmann-La Roche Ltd.
  • Chiasma
  • Camurus AB
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Somatostatin Analogue Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Somatostatin Analogue Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Somatostatin Analogue Drug Market Dynamics
  1. 2.1 Somatostatin Analogue Drug Industry Trends
  2. 2.2 Somatostatin Analogue Drug Industry Drivers
  3. 2.3 Somatostatin Analogue Drug Industry Opportunities and Challenges
  4. 2.4 Somatostatin Analogue Drug Industry Restraints
3 Somatostatin Analogue Drug Market by Company
  1. 3.1 Global Somatostatin Analogue Drug Company Revenue Ranking in 2025
  2. 3.2 Global Somatostatin Analogue Drug Revenue by Company (2021-2026)
  3. 3.3 Global Somatostatin Analogue Drug Company Ranking (2024-2026)
  4. 3.4 Global Somatostatin Analogue Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Somatostatin Analogue Drug Company Product Type and Application
  6. 3.6 Global Somatostatin Analogue Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Somatostatin Analogue Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Somatostatin Analogue Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Somatostatin Analogue Drug Market by Type
  1. 4.1 Somatostatin Analogue Drug Type Introduction
  2. 4.1.1 Octreotide
  3. 4.1.2 Lanreotide
  4. 4.1.3 Pasireotide
  5. 4.2 Global Somatostatin Analogue Drug Sales Value by Type
  6. 4.2.1 Global Somatostatin Analogue Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Somatostatin Analogue Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Somatostatin Analogue Drug Sales Value Share by Type (2021-2032)
5 Somatostatin Analogue Drug Market by Application
  1. 5.1 Somatostatin Analogue Drug Application Introduction
  2. 5.1.1 Acromegaly
  3. 5.1.2 Neuroendocrine Tumor (NET)
  4. 5.1.3 Others
  5. 5.2 Global Somatostatin Analogue Drug Sales Value by Application
  6. 5.2.1 Global Somatostatin Analogue Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Somatostatin Analogue Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Somatostatin Analogue Drug Sales Value Share by Application (2021-2032)
6 Somatostatin Analogue Drug Regional Value Analysis
  1. 6.1 Global Somatostatin Analogue Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Somatostatin Analogue Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Somatostatin Analogue Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Somatostatin Analogue Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Somatostatin Analogue Drug Sales Value (2021-2032)
  7. 6.3.2 North America Somatostatin Analogue Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Somatostatin Analogue Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Somatostatin Analogue Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Somatostatin Analogue Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Somatostatin Analogue Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Somatostatin Analogue Drug Sales Value (2021-2032)
  16. 6.6.2 South America Somatostatin Analogue Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Somatostatin Analogue Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Somatostatin Analogue Drug Sales Value Share by Country, 2025 VS 2032
7 Somatostatin Analogue Drug Country-level Value Analysis
  1. 7.1 Global Somatostatin Analogue Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Somatostatin Analogue Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Somatostatin Analogue Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Somatostatin Analogue Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Somatostatin Analogue Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Somatostatin Analogue Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Somatostatin Analogue Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd.
  2. 8.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Somatostatin Analogue Drug Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Eli Lilly & Co.
  14. 8.3.1 Eli Lilly & Co. Company Information
  15. 8.3.2 Eli Lilly & Co. Business Overview
  16. 8.3.3 Eli Lilly & Co. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly & Co. Somatostatin Analogue Drug Product Portfolio
  18. 8.3.5 Eli Lilly & Co. Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Somatostatin Analogue Drug Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 Tarveda Therapeutics Inc.
  26. 8.5.1 Tarveda Therapeutics Inc. Company Information
  27. 8.5.2 Tarveda Therapeutics Inc. Business Overview
  28. 8.5.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Portfolio
  30. 8.5.5 Tarveda Therapeutics Inc. Recent Developments
  31. 8.6 Ipsen Group
  32. 8.6.1 Ipsen Group Company Information
  33. 8.6.2 Ipsen Group Business Overview
  34. 8.6.3 Ipsen Group Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ipsen Group Somatostatin Analogue Drug Product Portfolio
  36. 8.6.5 Ipsen Group Recent Developments
  37. 8.7 F. Hoffmann-La Roche Ltd.
  38. 8.7.1 F. Hoffmann-La Roche Ltd. Company Information
  39. 8.7.2 F. Hoffmann-La Roche Ltd. Business Overview
  40. 8.7.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Portfolio
  42. 8.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
  43. 8.8 Chiasma
  44. 8.8.1 Chiasma Company Information
  45. 8.8.2 Chiasma Business Overview
  46. 8.8.3 Chiasma Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Chiasma Somatostatin Analogue Drug Product Portfolio
  48. 8.8.5 Chiasma Recent Developments
  49. 8.9 Camurus AB
  50. 8.9.1 Camurus AB Company Information
  51. 8.9.2 Camurus AB Business Overview
  52. 8.9.3 Camurus AB Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Camurus AB Somatostatin Analogue Drug Product Portfolio
  54. 8.9.5 Camurus AB Recent Developments
  55. 8.10 Boehringer Ingelheim International GmbH
  56. 8.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 8.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 8.10.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Portfolio
  60. 8.10.5 Boehringer Ingelheim International GmbH Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst